Cargando…

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients

Management of PD-1 blockade resistance in metastatic melanoma (MM) remains challenging. Immunotherapy or chemotherapy alone provides limited benefit in this setting. Chemo-immunotherapy (CIT) has demonstrated favorable efficacy and safety profiles in lung cancer. Our pre-clinical study showed that i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vera Aguilera, Jesus, Paludo, Jonas, McWilliams, Robert R., Zhang, Henan, Li, Ying, Kumar, Anagha B., Failing, Jarrett, Kottschade, Lisa A., Block, Matthew S., Markovic, Svetomir N., Dong, Haidong, Dronca, Roxana S., Yan, Yiyi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Original Articles: Clinical research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7331824/ https://www.ncbi.nlm.nih.gov/pubmed/32404734 http://dx.doi.org/10.1097/CMR.0000000000000669

Ejemplares similares

Bim and PD-1 identify effector CD8 T cells responsive to anti-PD-1 therapy in metastatic melanoma patients
por: Dronca, Roxana, et al.
Publicado: (2015)

Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy
por: Yan, Yiyi, et al.
Publicado: (2018)

Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era
por: Youland, Ryan S., et al.
Publicado: (2017)

18F-FDG PET response and clinical outcomes after stereotactic body radiation therapy for metastatic melanoma
por: Youland, Ryan S., et al.
Publicado: (2017)

Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles
por: Orme, Jacob J, et al.
Publicado: (2020)

Paradox-driven adventures in the development of cancer immunology and immunotherapy
por: Barham, Whitney, et al.
Publicado: (2019)

Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992–2011
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

A Gender Factor in Shaping T-Cell Immunity to Melanoma
por: Dronca, Roxana S., et al.
Publicado: (2015)

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations
por: DeLeon, Thomas T., et al.
Publicado: (2020)

A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses
por: Smith, Katherine E. R., et al.
Publicado: (2023)

Immune checkpoint molecules soluble program death ligand 1 and galectin‐9 are increased in pregnancy
por: Enninga, Elizabeth Ann L., et al.
Publicado: (2017)

Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy
por: Davidson, Tara M, et al.
Publicado: (2022)

Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy
por: Galli, Filippo, et al.
Publicado: (2020)

NKG7 Is a T-cell–Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy
por: Wen, Ti, et al.
Publicado: (2022)

Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
por: Thatcher, N., et al.
Publicado: (1977)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
por: Davidson, Tara, et al.
Publicado: (2022)

Therapy for metastatic melanoma: the past, present, and future
por: Finn, Laura, et al.
Publicado: (2012)

Dominant effects of Δ40p53 on p53 function and melanoma cell fate
por: Takahashi, Rie, et al.
Publicado: (2013)

OR32-02 Immune Checkpoint Inhibitor-Induced Hypophysitis Is Associated with Improved Overall Survival in Cancer Patients
por: Kotwal, Anupam, et al.
Publicado: (2020)

Chemo-immunotherapy by dual-enzyme responsive peptide self-assembling abolish melanoma
por: Wang, Yuhan, et al.
Publicado: (2023)

Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer
por: Wang, Yue, et al.
Publicado: (2023)

Beyond PD-1 Immunotherapy in Malignant Melanoma
por: Kwiatkowska, Dominika, et al.
Publicado: (2019)

Rational Design of Hyaluronic Acid-Based Copolymer-Mixed Micelle in Combination PD-L1 Immune Checkpoint Blockade for Enhanced Chemo-Immunotherapy of Melanoma
por: Zhou, Chaopei, et al.
Publicado: (2021)

Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG‐N0377, Alliance)
por: Vera Aguilera, Jesus, et al.
Publicado: (2018)

Endogenous tumor-reactive CD8(+) T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth
por: Liu, Xin, et al.
Publicado: (2013)

Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma
por: Rohatgi, Anjali, et al.
Publicado: (2021)

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events
por: Isik, Busra, et al.
Publicado: (2021)

Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy
por: Cai, Shuxian, et al.
Publicado: (2021)

Quantitative spatial evaluation of tumor-immune interactions in the immunotherapy setting of metastatic melanoma lymph nodes
por: Maus, Rachel L. G., et al.
Publicado: (2022)

The Role of Isothiocyanates as Cancer Chemo-Preventive, Chemo-Therapeutic and Anti-Melanoma Agents
por: Mitsiogianni, Melina, et al.
Publicado: (2019)

The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma
por: Mansfield, Aaron S., et al.
Publicado: (2013)

Long‐term outcome of immunologic autograft engineering
por: Porrata, Luis F., et al.
Publicado: (2022)

The need to optimize chemotherapy regimens for chemo-immunotherapy
por: Inamura, Kentaro, et al.
Publicado: (2022)

ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance
por: Orme, Jacob J., et al.
Publicado: (2020)

Understanding heterogeneous tumor microenvironment in metastatic melanoma
por: Yan, Yiyi, et al.
Publicado: (2019)

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
por: Nanamori, Hikaru, et al.
Publicado: (2022)

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
por: Liu, Xiangsheng, et al.
Publicado: (2021)

Contraction of T cell richness in lung cancer brain metastases
por: Mansfield, Aaron S., et al.
Publicado: (2018)

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
por: Luke, Jason J., et al.
Publicado: (2015)

Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy
por: Sahni, Sakshi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vjgmad2rj0c9bbsiqv3lo5tdu5